Jun 13, 2009

Infectious: Stay Away

"Infectious: Stay Away" is an exhibition at the Science Gallery, Dublin. From the official page:
THE INFECTION HAS TAKEN HOLD. Nearly 30,000 individuals have already been exposed to the INFECTIOUS exhibition in the Science Gallery. If you are brave enough to enter the containment zone on Pearse Street you are advised to wear protective clothing. INFECTIOUS is a major new exhibition exploring mechanisms of contagion and strategies of containment through science and art including a live epidemic simulation, an opportunity to have your DNA swabbed from your cheek and analysed and to get up close and intimate with a Petri dish as you cultivate the bacteria from your lips in our Kiss Culture experiment.

This seems like a good excuse to visit Dublin...




(Found via The Scientist)

Read the rest of the article... ------------------->

Jun 7, 2009

Social media for scientists

The following slidecast (that is, a slideshow including audio) is an excellent presentation by Mary Canady and William Gunn on social media for scientists. Topics covered: LinkedIn, Twitter, social bookmarking (delicious, citeulike, Mendeley), FriendFeed, science blogs.

If you are a scientist and you think social media is completely useless for you as a researcher... well, you are wrong and must watch this!



(Found via Twitter)

Read the rest of the article... ------------------->

Apr 25, 2009

Microbiology on Twitter?

Just for fun, I searched Twitter using some microbial-related terms (not many, as the query cannot be more than 140 characters long!). I have added an RSS feed for this query to the side bar on this blog.

Is Twitter useful for scientists or for science educators? For some, it seems to be.

Will Twitter (or a similar tool) be of general use among scientists in a near future? Perhaps.

As a new user, I know very little about Twitter. But interesting things are happening there.

I just find difficult to make sense out of most of them...

But I´ll keep trying.

And you should, too.

On Twitter, I am TwistedBacteria (obvious). But, definitely, you should be following at least MicroBytes and MicrobeWorld.

I also created a Twibe (a group of Twitter users interested in a common topic) called Microbiology.

(Thanks so much to Alan Cann for introducing me to the Twitter universe!)

Read the rest of the article... ------------------->

Mar 15, 2009

Twisted Bacteria welcomes lazy bloggers

'lazy days' by riot jane
Would you enjoy writing about the wonderful world of microbes but are too lazy (or busy) to start your own science blog? Well, then you might find more convenient to publish a post as a guest blogger in Twisted Bacteria.

Anybody is welcome - researchers, students, or just 'normal people' who enjoy reading and writing about science.

Anything related to microbes may qualify for a post at Twisted Bacteria - from hard science (such as a recent research finding that you find amazing) to science fiction, medicine, gardening, or food. Microbes are a part of our everyday life.

If you are interested, just send an email to TwistedBacteria AT gmail DOT com , explaining what you would like to write about.

(Blog entries are licensed under a Creative Commons Attribution-Noncommercial 3.0 Unported License)

Image credits: "lazy days" by riot jane. Source: Flickr.

Read the rest of the article... ------------------->

Aug 10, 2008

Encyclopedia of Life Sciences

Encyclopedia of Life Sciences
The Encyclopedia of Life Sciences (Wiley) contains more than 4,300 articles. At the time of writing this, over 50 articles were freely available as sample content.

A few examples of freebies:

  • Antibiotic resistance plasmids in bacteria
  • Bacterial transcription regulation
  • Bioinformatics
  • Dideoxy sequencing of DNA
  • DNA chips and microarrays
  • DNA cloning
  • Electrophoresis and blotting of DNA
  • Escherichia coli lactose operon
  • Experimental organisms used in genetics
  • Microorganisms: applications in molecular biology
  • Polymerase Chain Reaction (PCR)

Read the rest of the article... ------------------->

Aug 7, 2008

Gene transfer in bacterial arm races

The following videos are two short documentaries made by students in the MIT Graduate Program in Science Writing. Both films refer to a recent discovery of new antibiotics by scientists at the Massachusetts Institute of Technology and the University of Florida. But, please, don't say: "bah, another antibiotic discovering, so boring". What makes this an interesting story is not the particular antibiotics themselves (we'll see if they ever become useful), but the way they were discovered. Or should we say "created"?

It's been known for some time that the genomes of many microbes contain genes putatively coding for the production of many small molecules. Some of these molecules may have antibiotic, anticancer or other potentially useful activities. By looking at the genomic DNA sequence, scientists can often predict that such a microbe has the potential to produce specific metabolites, belonging to defined structural classes (polyketides, non-ribosomal peptides, glycosides, etc.). However, very often, the predicted metabolites are not detected when the microbe is cultured under standard laboratory conditions. Why is this? The usual explanation is that these molecules are only produced under specific circumstances that the microorganism faces in its natural environment.

ResearchBlogging.orgWith this idea in mind, the above mentioned researchers tried to find antibiotics in the cultures of a bacterium called Rhodococcus fascians (let's call it "Rhodo"). Rhodo belongs to a group of bacteria known as actinomycetes, which are well-known antibiotic producers and whose genomes are rich in information coding for the synthesis of potentially useful metabolites. The scientists cultured the microorganism under a variety of conditions: they tried both standard and unusual ones (starvation, sub-optimal temperatures or culture media, etc.). However, no antibiotic activity was ever detected.

So, they tried to "stress" Rhodo by adding another microbe in the same flasks: the name of the second partner was Streptomyces padanus ("Strepto", for short). Strepto produces a potent antibiotic (actinomycin) that kills bacteria such as Rhodo. So, what was the point? Rhodo died in all flasks, didn't it? Well, not in all of them. In one particular flask (out of hundreds), Rhodo not only survived but actually exterminated Strepto! The "Super-Rhodo" did this by producing a new antibiotic substance, never seen before. Moreover, Super-Rhodo was able to do this thanks to a piece of DNA that Rhodo stole from Strepto!

Both documentaries refer to the same story, but they use remarkably different styles. Please watch both of them, and post a comment if you want to share your thoughts (about them or about the story).

The first video is War in a Petri Dish, by Grace Chua, Allyson Collins, and Lissa Harris:



The second video is Shot in the Dark, by Andrew Moseman, Rachel VanCott, Megan Rulison, and Ashley Yeager:



There are some scientific aspects that may need some clarification. The initial idea was that Rhodo contained the genetic potential to make antibiotics, and the genes responsible for this were only "switched on" under certain unknown circumstances. This might be correct, but the mentioned results don't clearly validate it. When Rhodo faced a Strepto attack, it simply died. The only survivor (and now a killer itself), Super-Rhodo, had acquired genetic material from its enemy. This extra piece of DNA was essential for production of the new compounds. Although full details have yet to be published, it is not clear if the transferred DNA contained all, or some, of the genes coding for biosynthetic enzymes for antibiotic production. The new antibiotics are not related to actinomycin; however, it is possible that Strepto is able to produce them, in addition to actinomycin (again, under certain unknown circumstances...). Alternatively, the real effect of the extra DNA might be just regulatory, coding for some factor that induced the "switching on" of Rhodo's own genes. We'll wait for the answers to these doubts.

Scholar article:
K. Kurosawa, I. Ghiviriga, T.G. Sambandan, P.A. Lessard, J.E. Barbara, C. Rha, A.J. Sinskey (2008). Rhodostreptomycins, Antibiotics Biosynthesized Following Horizontal Gene Transfer from Streptomyces padanus to Rhodococcus fascians Journal of the American Chemical Society, 130 (4), 1126-1127 DOI: 10.1021/ja077821p

Related link:
Deadly mycelia: predatory streptomycetes. Twisted Bacteria (Jan. 15, 2008).

Read the rest of the article... ------------------->

Jul 8, 2008

A new way to make polyketides

A model of the PKS12 proteinPolyketides are a class of natural products isolated from microbes, plants and invertebrates which includes an impressive number of clinically effective drugs with diverse activities. To name a few examples: erythromycin (antibiotic), rapamycin (immunosuppressive), amphotericin (antifungal), avermectin (antiparasitic), and doxorubicin (anticancer). As other natural products do, polyketides may play disparate roles in the producing organisms, from defensive weapons (inhibiting growth of competitors, or acting against predators) to signaling molecules (working as messengers between social organisms). In Mycobacterium tuberculosis, some polyketides are key intermediates in the synthesis of complex lipids. These lipids are important components of the unusually thick cell envelope, and help the microbe to be a successful pathogen. Therefore, the study of polyketide synthesis in this bacterium may lead to the design of specific inhibitors as new anti-mycobacterial drugs.

ResearchBlogging.orgPolyketides are produced through a stepwise condensation of simple carboxylic acid precursors, resembling fatty acid biosythesis. This task is performed by enzymes known as polyketide synthases (PKSs). There are several types of PKSs, from relatively simple proteins to large multienzymatic complexes possessing tens of catalytic sites. They use any of two general mechanisms: (1) modular — in which each set of catalytic sites is used only once during the biosynthetic process, and (2) iterative — in which the same set of active sites is used repeatedly. This week in PLoS Biology, Rajesh Gokhale and colleagues present their research involving a peculiar PKS from M. tuberculosis. The PKS12 protein is encoded by the largest gene in the microbe's genome, and participates in the synthesis of an antigenic phosphoglycolipid. Most remarkably, this PKS appears to use a new hybrid "modularly iterative" mechanism for polyketide synthesis. Several molecules of the PKS12 protein join together to form a supramolecular assembly, which performs repetitive cycles of iterations. The protein assembly is formed by specific intermolecular interactions between N- and C-terminus linkers. This study provides another example of the catalytic and mechanistic versatility of PKSs — natural product biosynthesis is an inexhaustible source for new biochemistry!

Citation (open access):
Chopra T, Banerjee S, Gupta S, Yadav G, Anand S, Surolia A, Roy RP, Mohanty D, Gokhale RS (2008). Novel intermolecular iterative mechanism for biosynthesis of mycoketide catalyzed by a bimodular polyketide synthase. PLoS Biology 6(7), e163. DOI: 10.1371/journal.pbio.0060163

Image: model of the PKS12 protein, modified from Figure 5 of the cited article.


Related links:



Read the rest of the article... ------------------->

Jul 1, 2008

An 'open source' approach to drug discovery

Pill bottle. Photo by net_efekt

Why should we worry about intellectual property protection for infectious diseases and diseases of the poor? Why can't we share our ideas and brains to create an open source platform for drugs for these diseases in the same way that the human genome has been sequenced and the Internet developed?
These are some questions posed by geneticist Samir Brahmachari in an interview published at SciDev.net. It makes an interesting reading.

Samir Brahmachari is the director general of India's Council of Scientific and Industrial Research (CSIR), a network of 38 government laboratories. He is starting an 'open source' approach to drug discovery, starting with tuberculosis (TB). His aim: a system where researchers all over the world work on different areas of drug design and deposit their findings into an open database for others to use and comment on — particularly for infectious diseases that affect the world's poor.

Here I am just gathering a few selected parts from the interview, and adding (see below) a collection of links related to open-source drug discovery.

Excerpts from the interview:
Most public-funded institutions do a lot of biomedical research but the last mile of drug discovery is left to the pharmaceutical industry — which is a 'closed-door' activity.

My idea is that affordable drugs are a right for all, and all drugs can be made available. When it comes to TB or diseases of the poor — where the market incentive is very small — it is not possible to convince the pharmaceutical companies to work on these drugs. Therefore it is the responsibility of public-funded institutions to participate.
Targeted drugs that are market driven — or that rich people can afford — can be made by the [patent-protected] route. But for drugs that are not driven by the market and are needed by the poor, open source is an advantage.
An open source approach runs against the current global emphasis on tightening patents and intellectual property rights. Will it survive opposition from powerful pharmaceutical companies inside and outside India?

On the contrary, you will be surprised to learn that, in the case of TB, many pharmaceutical companies have shown interest in this concept and responded to my initiative. They would like to see a drug breakthrough because of the huge number of patients who need it.

Also, today the private sector is increasingly talking about corporate social responsibility. Private companies are becoming conscious of their social responsibility and many would like to join such initiatives. And there are many private non-profit foundations, such as Bill Gates' Foundation, who support affordable drugs initiatives.

Are you not worried that open source discovery will reduce the incentive for pharmaceutical companies to invest in research, and that public sources will lack the funds to make up the difference?

I am not worried about that. If the private companies do not come forward with research and development in neglected diseases, then it becomes the obligation and responsibility of the public-funded institutes to undertake the research. India is now no longer a poor country and the Indian government can afford to invest money for such research.
Even big pharmaceutical companies, such as AstraZeneca, and leading universities, such as Berkeley, have shown interest in collaboration. Sabeer Bhatia, a founder of Microsoft's Hotmail, has agreed to support us by developing the software.
How applicable is open source to other technological areas?

An important point — somewhat overlooked — is the participation of brilliant minds in the open source model. Where knowledge is free, brilliance flourishes. I believe that, in principle, technology areas such as energy, water and food can also benefit from the open source model. In the case of energy, we may invite solutions to tap solar energy, wind energy, hydropower and other sectors. Similar methods could be adopted in other areas.
When it comes to infectious diseases, compulsory licensing [where pharmaceutical companies must allow their product to be produced cheaply by a country in a medical emergency] should be used on all drug patents so that we can make the drug at low cost and make it affordable for poor people.


The interview is freely available at:
T. V. Padma. Q&A: Advocating open source drugs. SciDev.Net (June 12, 2008).


Links related to open-source drug discovery:



Image credits: Pill bottle by net_efekt (Christian Guthier). Source: Flickr.

Read the rest of the article... ------------------->

Jun 30, 2008

Why don't plants have any chlamydial symbionts?

Electron micrograph of a cell infected by Chlamydia trachomatisIt seems that all known chlamydiae are obligate intracellular symbionts -- they can only reproduce inside eukaryotic cells, and remain metabolically inactive outside of their hosts (a virus-like lifestyle). Chlamydiae can infect different kinds of animals (mammals, birds, fishes, arthropods, crustaceans) and unicellular eukaryotes (such as environmental amoebae). Remarkably, chlamydiae have never been found in plants or in other plastid-containing organisms (red and green algae, plants and glaucophytes, together known as Plantae or Archaeplastida).

On the other hand, as I have explained in a previous post (A cell potpourri: eukaryotes and their organelles), an important number of Archaeplastida genes are derived from ancient chlamydiae, suggesting a long-term symbiosis between ancestors of chlamydiae and Archaeplastida. The bacterial endosymbiont was later lost, leaving some of its genes behind.

So, the question is: why don't present-day Archaeplastida have any chlamydial symbionts (parasitic, mutualistic, commensal)? Why can't they be infected, once more, by chlamydiae?

I may think of some possible answers:

(1) Actually, there are chlamyidial symbionts in Archaeplastida. We just haven't found them. (Have we looked for them?)

(2) Archaeplastida are not special: other eukaryotic lineages appear to lack chlamydial symbionts (just a hypothesis, I have no idea). In other words, chlamydiae are able to infect cells from only specific eukaryotic lineages. (How wide is chlamydial host-range? Has anybody tried to infect Archaeplastida cells with chlamydiae?)

(3) Archaeplastida are special: after being infected by chlamydia-like bacteria, the Archaeplastida lineage became resistant to over-infection by other chlamydiae. (If this is the case, it would be nice to know the molecular mechanisms responsible for the resistance. Can we make an Archaeplastida cell susceptible to infection by knocking-out specific genes? Are these genes derived from chlamyidiae? Or, the other way around, can we make an Archaeplastida cell susceptible to infection by adding specific genes from other eukaryotes? This knowledge could be useful to design new anti-chlamydial therapies.)

You can contribute to this discussion here (post a comment), or at the PLoS ONE site where a relevant article was published (Chlamydiae has contributed at least 55 genes to Plantae with predominantly plastid functions).


Related links:


Image:
Electron micrograph of a cell infected by Chlamydia trachomatis. © American Society for Microbiology. Reference: Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol. Rev. (1994) 58, 686-699.

Read the rest of the article... ------------------->

Jun 28, 2008

Relaxing at the microscope

A video from YouTube (Microorganism Spacial Journey) showing microscopic images of microbes and other tiny beasts, accompanied by a very relaxing music.


Read the rest of the article... ------------------->

Jun 17, 2008

A cell potpourri: eukaryotes and their organelles

Plant cell (artwork) - Photo by R.W.W. (Ambra Galassi)According to the endosymbiotic theory, eukaryotic organelles (mitochondria, chloroplasts) are the remains of certain bacteria that established intimate associations with eukaryote ancestors. This theory is widely supported by biochemical, genetic and proteomic evidences. A take-home message may be: a bacterium became an endosymbiont, then degenerated, and voilà, turned into an organelle. But that's an oversimplification. A full story should include an active participation of the host, some horizontal gene transfer from different microbial sources and, most likely, the involvement of other endosymbiotic partners that became extinct long time ago.

The origin of mitochondria, through the association between a eukaryotic ancestor and an alpha-proteobacterium (perhaps similar to Rickettsia) was a crucial, early event: thusfar, all eukaryotes examined possess mitochondria or mitochondria-related compartments, or at least some genes derived from such an organelle. About 1.5 billion years ago, a cyanobacterium joined the partnership to give rise to plastids in a common ancestor of red and green algae, land plants and glaucophytes (together the Archaeplastida). Although the identity of the cyanobacterial symbiont is far from clear, recent studies support the hypothesis that it might be similar to contemporary Nostoc or Anabaena. Many of these filamentous, nitrogen-fixing cyanobacteria are endosymbionts, which generally provide nitrogen to their hosts (this agrees with suggestions that nitrogen fixed by the endosymbiont might have played an important role during the origin of plastids). These organelles were later spread through secondary endosymbioses, that is, plastid-containing eukaryotes were engulfed by other eukaryotes; this process has occurred several times and has produced an astonishing diversity of photosynthetic organisms.

For a bacterium to become a permanent endosymbiont and, eventually, an organelle, some new functions had to be developed, or re-adapted from old ones. Firstly, a controlled exchange of metabolites ("food", waste products, ions) had to be established between the host cell and the endosymbiont. Additionally, the two partners had somehow to coordinate cell division, to assure that at least one endosymbiont cell was included in each daughter cell when the host reproduced.


Gene loss and gene transfer to the nucleus


On the other side, long-term endosymbionts could get rid of many functions that were required by free-living bacteria, and many unnecessary genes were lost. In general, genomes of mitochondria and plastids are about 10-20 times smaller than genomes of present-day Rickettsia and free-living cyanobacteria, respectively. Actually, the number of protein-coding genes in organellar genomes is very small (3-70 for mitochondria, 50-200 for chloroplasts). Does this mean that only 3 (or 50) proteins are needed for a mitochondrion (or chloroplast) to function? Of course not — these organelles are complicated molecular machines, requiring the coordinated action of several hundreds or thousands of different proteins. However, most of these proteins are not coded in the organelle genome but in the nuclear DNA. That is, many bacterial genes were lost, and most of the remaining genes were transferred to the host genome. Apparently, the nucleus is a safer environment for DNA: deleterious mutations may accumulate at a faster pace in organelles, due to a higher mutation rate caused by oxygen free-radicals, in addition to the non-recombining nature and small population size of organelle genomes. Then, it is not clear why mitochondria and chloroplasts retain a genome at all. Perhaps each type of organelle needs to keep a minimum set of key genes that are subject to a fast and tight regulation depending on local (organelle) conditions; or the encoded proteins cannot be efficiently transported into the organelle. On the other hand, some organelles do exist that appear to lack a genome — the hydrogenosomes, which might be derived from mitochondria.

Once the endosymbiont genes landed on the nuclear genome, they had to suffer some modifications to be properly expressed in the new location. Additionally, nuclear genes are, by default, translated into proteins in the host cytoplasm — if these proteins need to function in the endosymbiont cell, they have to be properly targeted and directed to the right compartment. This required the development, or re-adaptation, of an efficient system for protein targeting and translocation.


With a little help from some friends

Interestingly, both cellular partners were active players in organelle establishment: all key functions required for endosymbiosis were driven by combinations of endosymbiont- and host-derived proteins. Organelle proteomes are a potpourri of proteins with diverse origins: a surprisingly large pool was derived from the host, while other proteins were provided by multiple symbionts and/or horizontal gene transfer. A study of the yeast mitochondrial proteome showed a predominant eukaryotic origin (about 50%), and only about 15% of the proteins came from alpha-proteobacteria; the remainder had other prokaryotic origin. In the case of the plastid proteome, most proteins (1,000-1,500) are derived from cyanobacteria, and several hundreds are of eukaryotic origin.


Chlamydiae and the origin of plastids


ResearchBlogging.orgRecent sudies have shed new light on the origin of plastids, suggesting the involvement of another group of bacteria, the chlamydiae. Present-day chlamydiae live as obligate intracellular parasites in eukaryotic cells. Many chlamydiae are pathogens of humans and animals, while others are found as endosymbionts in amoebae and insects; thusfar, they have not been found in plants or other plastid-containing eukaryotes. Nevertheless, it was known for some time that an unexpected number of chlamydial genes were most similar to plant homologs, most of which contained a plastid-targeting signal. This observation prompted several hypotheses, including an ancestral evolutionary relationship between chlamydiae and the cyanobacterial donor of the plastid, and horizontal gene transfer between the two groups. It was also suggested that plants might have acquired these genes through intermediate vectors such as infected insects.

A phylogenomic analysis of 17 Archaeplastida species has shown that at least 55 genes were transferred between chlamydiae and primary photosynthetic eukaryotes. Two thirds of the genes appear to encode plastid proteins, while the rest may have other cellular functions (including mitochondrial functions). The data provided strong evidence for a long-term symbiotic association between chlamydia-like cells and the Archaeplastida ancestor. It is possible that both cyanobacterial and chlamydial endosymbionts may have co-existed in the cell. It is not clear if the chlamydial association consisted of a recurrent infection by one or more specific endoparasites (as occurs in contemporary chlamydiae and their eukaryotic hosts), or an organelle-like endosymbiosis. While the cyanobacterium provided the photosynthetic function and was retained as an organelle, the chlamydiae supplied a number of key genes, including those coding for some metabolite transporters used by the plastid (especially the ADP/ATP translocator). This facilitated the communications between the cyanobacterium and the eukaryotic cell. However, the chlamydial partner was eventually eliminated by the host, once it became an unnecessary burden.

The origin of plastids
Endosymbionts or organelles?

The establishment of plastids from cyanobacteria probably occurred only once in a common ancestor of Archaeplastida; this was thought to be the only example of primary endosymbiosis leading to a photosynthetic eukaryote. However, another independent case of primary endosymbiosis is now known: Paulinella chromatophora is an autotrophic amoeba that contains two photosynthetic bodies that appear to have been acquired much more recently than the plastids of all other eukaryotes by the uptake of a Synechococcus-like cyanobacterium. Other examples of extreme bacterial endosymbionts, or pseudo-organelles, include Buchnera (in aphid insects) and Carsonella (with a tiny 160-kilobase genome, in psyllid insects). Additionally, the transfer of a complete genome from an endosymbiont to the host chromosome has been well documented for Wolbachia (in several insects).

Nature is unfinished...



Scholar articles (open access):

  • Huang, J., Gogarten, J. (2007). Did an ancient chlamydial endosymbiosis facilitate the establishment of primary plastids? Genome Biology, 8(6), R99. DOI: 10.1186/gb-2007-8-6-r99
  • Moustafa, A., Reyes-Prieto, A., Bhattacharya, D., DeSalle, R. (2008). Chlamydiae has contributed at least 55 genes to Plantae with predominantly plastid functions. PLoS ONE, 3(5), e2205. DOI: 10.1371/journal.pone.0002205

Related links:

Image credits:
  • Unnamed artwork of a plant cell: Photo by R.W.W. (Ambra Galassi) on Flickr.
  • Chlamydiae and the origin of plastids: Figure 4 from Moustafa A, Reyes-Prieto A, Bhattacharya D (2008) Chlamydiae Has Contributed at Least 55 Genes to Plantae with Predominantly Plastid Functions. PLoS ONE 3(5): e2205.

Read the rest of the article... ------------------->

Jun 3, 2008

Martian microbes: remember we are friends

I have always been a huge fan of life at the cellular level...



(Hat tip: The Tree of Life)

Read the rest of the article... ------------------->

May 30, 2008

Merck halts natural products research

Streptomyces cattleya, a microbe that produces thienamycinBad news: Merck has decided to close down its natural product research facilities. This means the end of CIBE (Centro de Investigación Básica de España) — or Spanish Center for Biological Research — located in Madrid, Spain. Since its creation in 1954, this center has been dedicated to the discovery of new compounds of therapeutical potential produced by microbes. These efforts led to the development of several useful medicines, including antibiotics (fosfomycin, cefoxitin, thienamycin), cholesterol-lowering drugs (lovastatin), and antifungal agents (caspofungin). In May 2006, Merck researchers hit the news with the discovery of platensimycin, a natural product belonging to a new class of antibiotics.

According to Chemical & Engineering News, the high costs are behind the decision to eliminate natural products research. Merck spokesman Ian R. McConnell explains to C&EN:

"The investment involved in finding these chemicals in the environment is significant. The products that came out of our effort have been significant as well, but that was over a 50-year period"
Sad, but true. Many thousands of natural samples need to be screened in order to detect a bunch of potentially useful compounds, most of which will never become a marketed drug. Turning a promising natural product into a useful medicine takes much effort and time (over 10 years) and, hence, money. So, perhaps it is understandable that most pharmaceutical companies dedicate only a very small fraction of their resources, if any, to natural product drug discovery.

However, even with that little dedication, many medicines in the market have a natural origin, being based in substances originally isolated from plants, microbes, etc. Can we imagine the possible results of investing in natural product research as many resources as those dedicated to chemical synthesis?

Natural compounds often have bizarre, complicated chemical structures and exert their biological effects through unexpected mechanisms. They are the result of an on-going combinatorial chemistry performed by organisms since the origin of life.

Are chemists that good?



Related links

A) About job cuts at Merck:
B) About CIBE:
C) About natural products in drug discovery:


Image credits:
Digital Atlas of Actinomycetes. Copyright: Society for Actinomycetes Japan. Contributor: S. Mochales. This strain produces β-lactam antibiotics, thienamycins. It has the color of cattleya orchids.

Read the rest of the article... ------------------->

May 29, 2008

EcoliHub: all together now


EcoliHub is a website sponsored by the U.S. National Institutes of Health, trying to bring together researchers interested in Escherichia coli with the most up-to-date information and data. From the EcoliHub site:

Sixty years of study have made Escherichia coli the most deeply understood organism at the molecular level. Much of what we know about cellular processes can be traced to fundamental discoveries in E. coli.
In spite of its great importance as a model organism, information about E. coli is distributed among many online resources. EcoliHub uses web services to make seamless bidirectional connections between E. coli resources, thereby enabling the full use of existing knowledge and supporting cutting-edge research into the molecular basis of life.

Read the rest of the article... ------------------->

May 26, 2008

Immune Atack, a video game

From the official Immune Attack website:

"The Federation of American Scientists (FAS) presents Immune Attack™, an educational video game that introduces basic concepts of human immunology to high school and entry-level college students. Designed as a supplemental learning tool, Immune Attack aims to excite students about the subject, while also illuminating general principles and detailed concepts of immunology."



(I can't help thinking of Fantastic Voyage...)

Related links:

Read the rest of the article... ------------------->